羚锐制药
(600285)
| 流通市值：124.15亿 | | | 总市值：124.43亿 |
| 流通股本：5.66亿 | | | 总股本：5.67亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 3,041,361,639.17 | 2,099,205,515.81 | 1,020,755,870.55 | 3,500,831,286.92 |
| 营业收入 | 3,041,361,639.17 | 2,099,205,515.81 | 1,020,755,870.55 | 3,500,831,286.92 |
| 二、营业总成本 | 2,332,076,667.21 | 1,580,082,239.98 | 780,335,122.23 | 2,768,148,768.85 |
| 营业成本 | 577,299,015.5 | 391,972,006.89 | 237,149,305.75 | 846,562,046.44 |
| 税金及附加 | 40,908,722.15 | 28,113,444.44 | 14,102,971.17 | 45,360,022.01 |
| 销售费用 | 1,437,387,330.38 | 994,497,354.35 | 470,887,517.37 | 1,596,930,049.01 |
| 管理费用 | 176,993,366.27 | 106,577,838.9 | 37,493,615.65 | 166,656,502.54 |
| 研发费用 | 104,600,773.85 | 63,060,862.63 | 22,799,572.17 | 131,525,319.54 |
| 财务费用 | -5,112,540.94 | -4,139,267.23 | -2,097,859.88 | -18,885,170.69 |
| 其中:利息费用 | 3,260,401.6 | 1,596,630.86 | 506,504.11 | -767,494.16 |
| 其中:利息收入 | 8,592,375.19 | 6,040,838.42 | 2,470,839.15 | 18,824,724.53 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 800,729.64 | -1,998,717.96 | -375,621.82 | -10,490.56 |
| 加:投资收益 | 36,727,423.67 | 24,131,253.21 | 12,128,768.89 | 40,214,203.52 |
| 资产处置收益 | 4,739,381.35 | 4,703,827.72 | 411,939.39 | 12,061.9 |
| 资产减值损失(新) | -58,216.77 | -35,682.24 | -4,445.36 | -501,754.11 |
| 信用减值损失(新) | -9,625,302.34 | -6,382,347.75 | -2,990,219.63 | -5,719,044.83 |
| 其他收益 | 16,495,599.62 | 11,929,463.94 | 4,092,967.8 | 43,624,190.56 |
| 四、营业利润 | 758,364,587.13 | 551,471,072.75 | 253,684,137.59 | 810,301,684.55 |
| 加:营业外收入 | 1,415,536.05 | 1,285,243.01 | 56,716.69 | 22,904,745.34 |
| 减:营业外支出 | 2,221,330.37 | 1,208,773.01 | 71,961.72 | 5,633,433.03 |
| 五、利润总额 | 757,558,792.81 | 551,547,542.75 | 253,668,892.56 | 827,572,996.86 |
| 减:所得税费用 | 104,022,269.61 | 75,679,042.87 | 36,935,103.46 | 104,988,304.87 |
| 六、净利润 | 653,536,523.2 | 475,868,499.88 | 216,733,789.1 | 722,584,691.99 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 653,536,523.2 | 475,868,499.88 | 216,733,789.1 | 722,584,691.99 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 650,932,609.77 | 474,385,806.53 | 216,817,540.12 | 722,550,720.15 |
| 少数股东损益 | 2,603,913.43 | 1,482,693.35 | -83,751.02 | 33,971.84 |
| 扣除非经常损益后的净利润 | 605,225,066.74 | 442,499,140.75 | 203,920,717.25 | 642,150,571.99 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 1.15 | 0.84 | 0.38 | 1.29 |
| (二)稀释每股收益 | 1.15 | 0.83 | 0.38 | 1.28 |
| 八、其他综合收益 | 4,885,283.79 | 6,235,719.57 | 6,311,122.23 | -52,945,072.92 |
| 归属于母公司股东的其他综合收益 | 4,864,027.4 | 6,223,701.99 | 6,301,809.7 | -53,020,784.44 |
| 九、综合收益总额 | 658,421,806.99 | 482,104,219.45 | 223,044,911.33 | 669,639,619.07 |
| 归属于母公司股东的综合收益总额 | 655,796,637.17 | 480,609,508.52 | 223,119,349.82 | 669,529,935.71 |
| 归属于少数股东的综合收益总额 | 2,625,169.82 | 1,494,710.93 | -74,438.49 | 109,683.36 |
| 公告日期 | 2025-10-30 | 2025-08-20 | 2025-04-26 | 2025-04-26 |
| 审计意见(境内) | | | | 标准无保留意见 |